#

Dailypharm Korea will be available without login access until the end of December 2019.
Membership login access would be required from February 2020 to access more news and website services.
Dailypharm Live Search Close
  • EASY-ON opens up new opportunity to Xarelto amid COVID-19
  • by Eo, Yun-Ho | translator Byun Kyung A | Jun 19, 2020 06:24am
Interview on Xarelto PM Jung Changho at Bayer Korea
“Imbalanced information among healthcare providers resolved with non-contact detailing, more benefits to patients”
“One-on-one detailing with experienced nurse, aiming for registering 2,000 members this year”
 ▲ PM Jung Changho
COVID-19 has brought dramatic changes to our lives. Witnessing these changes, scholars stress the importance of responding and planning for the prospective changes in the post-coronavirus era.

And many pharmaceutical companies are also seeking for new changes in business model amid COVID-19 pandemic.

For the pharmaceutical industry, the novel infectious disease has been increasingly limiting the conventional sales activity, which highlighted the importance of non-contact multi-channel marketing. Now the online-based marketing tools are emerging as an answer, and companies are taking the cue to expand various non-contact sales channels like one-on-one detailing service, web symposium and e-catalogue.

In March, when COVID-19 was spreading fast in Korea, Bayer Korea launched non-contact detailing service ‘EASY-ON’ and swiftly tackled on the changes in the society’s trend.

EASY-ON is an online video consulting solution that provides latest clinical findings and anti-coagulant prescription related medical information for primary healthcare institutes like private clinics to better manage chronic atrial fibrillation. The program has specialized nurse with clinical experience as a consultant to engage with the healthcare providers. .

Daily Pharm interviewed Product Manager (PM) Jung Changho, who led the EASY-ON project launch, for the story of the present and future of non-contact sales.

 ▲ Bayer

-Please give us a short introduction to yourself for the readers

Started as a medical representative in the cardiovascular sector since 2009, I joined the Xarelto sales division in 2016. Currently, I am in charge of planning and operating the EASY-ON project in the marketing team, and it has been over a year being the PM for Xarelto team.

-Marketing and sales around the world are largely obstructed by the COVID-19 pandemic. What kind of changes have you experienced after the outbreak, and how is the Xarelto team responding to the situation?

The non-contact marketing and sales back in the day used to lack the drive. Of course, many pharmaceutical companies have been continuously working on remote multi-channel marketing before, but after the outbreak, the companies are more eager to diversify the communication channels and try them in real life.

As the conventional sales are deeply rooted in face-to-face engagement, I was always skeptical of other channels and their effect.

But, with the recent incident, I have learned the clients are more ready to accept the new system than how we expected, and that they are more open and positive to review a new communication channel.

-Apparently, EASY-ON program launch was planned before the COVID-19?

Actually, the plan for EASY-ON predates the COVID-19 outbreak—it was initially planned to improve the atrial fibrillation patient management. And the project took the momentum as the outbreak started in the time of the launch.

The objective of the EASY-ON is to inform private clinic healthcare providers to adequately manage atrial fibrillation patients, and to fixed imbalanced information caused when using an anticoagulant.

Unlike general hospitals, private clinics have contacted the company through various channels to query prescription related information, which shows the information asymmetry between the two. And this is how EASY-ON came about. The ultimate goal of the project is to educate the healthcare providers for patients to truly benefit from treatment options.

-How is the program generally operated?

The first and the most important benefit of EASY-ON is having seasoned specialist nurse to give consultation via video conference call. The second benefit is that the program focuses on atrial fibrillation, which tends to require more intricate care and treatment compared to other chronic disease. The healthcare providers can access relevant in-depth information, because EASY-ON specializes in atrial fibrillation and relevant treatment information,.

About three months since the launch in March, approximately 200 healthcare providers have joined the program so far. It constantly provides scheduled consulting service to the members. The EASY-ON platform offers overall ten basic learning materials based on basic information of the health condition, which is accessible on demand after the consulting session.

-General hospital and private clinic healthcare providers are torn between the prescription options of non-Vitamin K antagonist oral anticoagulants (NOAC) like Xarelto and initial care. Between the two clientele, which does Bayer tries to put more focus on?

Most importantly, no patient should be left behind by any one of them. So both are very important channels we need to take care of.

At the moment, general hospitals are encouraging patients to be diagnosed at general hospital and to manage the condition at clinics. And clinics anticipate contributing in the initial anticoagulant treatment in atrial fibrillation patients. Bayer’s biggest mission is to have the patients with atrial fibrillation to receive adequate treatment, regardless of general hospital or clinic, and to manage the condition properly.

-Any memorable anecdote with the EASY-ON to share?

A private clinic in a hard to access remote region gave a quite memorable feedback.

Despite the needs for the anticoagulant treatment information, the healthcare provider there did not have a good and efficient access to the information. But in the end they expressed gratitude for our EASY-ON program when basic information and key information needed for seeing a patient were provided through a video call platform.

-What’s next for EASY-ON?

The project is aiming to secure 2,000 members within this year. Although the service has been reactively responding, the company is preparing a channel to academically engage with general hospital professors in real time for their unmet needs.

For the EASY-ON clients, web symposium consisting of specialized consulting webinars would be organized to talk about differences in each clinical trial and solution in each case. And other informative materials like FAQ or newsletter would be disseminated to the EASY-ON members to answer their queries on NOAC.
  • 0
Reader Comment
0
Anonymity comment Write Operate Rule
Colse

댓글 운영방식은

댓글은 실명게재와 익명게재 방식이 있으며, 실명은 이름과 아이디가 노출됩니다. 익명은 필명으로 등록 가능하며, 대댓글은 익명으로 등록 가능합니다.

댓글 노출방식은

댓글 명예자문위원(팜-코니언-필기모양 아이콘)으로 위촉된 데일리팜 회원의 댓글은 ‘게시판형 보기’와 ’펼쳐보기형’ 리스트에서 항상 최상단에 노출됩니다. 새로운 댓글을 올리는 일반회원은 ‘게시판형’과 ‘펼쳐보기형’ 모두 팜코니언 회원이 쓴 댓글의 하단에 실시간 노출됩니다.

댓글의 삭제 기준은

다음의 경우 사전 통보없이 삭제하고 아이디 이용정지 또는 영구 가입제한이 될 수도 있습니다.

  • 저작권·인격권 등 타인의 권리를 침해하는 경우

    상용 프로그램의 등록과 게재, 배포를 안내하는 게시물

    타인 또는 제3자의 저작권 및 기타 권리를 침해한 내용을 담은 게시물

  • 근거 없는 비방·명예를 훼손하는 게시물

    특정 이용자 및 개인에 대한 인신 공격적인 내용의 글 및 직접적인 욕설이 사용된 경우

    특정 지역 및 종교간의 감정대립을 조장하는 내용

    사실 확인이 안된 소문을 유포 시키는 경우

    욕설과 비어, 속어를 담은 내용

    정당법 및 공직선거법, 관계 법령에 저촉되는 경우(선관위 요청 시 즉시 삭제)

    특정 지역이나 단체를 비하하는 경우

    특정인의 명예를 훼손하여 해당인이 삭제를 요청하는 경우

    특정인의 개인정보(주민등록번호, 전화, 상세주소 등)를 무단으로 게시하는 경우

    타인의 ID 혹은 닉네임을 도용하는 경우

  • 게시판 특성상 제한되는 내용

    서비스 주제와 맞지 않는 내용의 글을 게재한 경우

    동일 내용의 연속 게재 및 여러 기사에 중복 게재한 경우

    부분적으로 변경하여 반복 게재하는 경우도 포함

    제목과 관련 없는 내용의 게시물, 제목과 본문이 무관한 경우

    돈벌기 및 직·간접 상업적 목적의 내용이 포함된 게시물

    게시물 읽기 유도 등을 위해 내용과 무관한 제목을 사용한 경우

  • 수사기관 등의 공식적인 요청이 있는 경우

  • 기타사항

    각 서비스의 필요성에 따라 미리 공지한 경우

    기타 법률에 저촉되는 정보 게재를 목적으로 할 경우

    기타 원만한 운영을 위해 운영자가 필요하다고 판단되는 내용

  • 사실 관계 확인 후 삭제

    저작권자로부터 허락받지 않은 내용을 무단 게재, 복제, 배포하는 경우

    타인의 초상권을 침해하거나 개인정보를 유출하는 경우

    당사에 제공한 이용자의 정보가 허위인 경우 (타인의 ID, 비밀번호 도용 등)

  • ※이상의 내용중 일부 사항에 적용될 경우 이용약관 및 관련 법률에 의해 제재를 받으실 수도 있으며, 민·형사상 처벌을 받을 수도 있습니다.

    ※위에 명시되지 않은 내용이더라도 불법적인 내용으로 판단되거나 데일리팜 서비스에 바람직하지 않다고 판단되는 경우는 선 조치 이후 본 관리 기준을 수정 공시하겠습니다.

    ※기타 문의 사항은 데일리팜 운영자에게 연락주십시오. 메일 주소는 dailypharm@dailypharm.com입니다.

Write
Write
recently Agree DisAgree
If you want to see the full article, please JOIN US (click)